Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
7Customers
2Debt Items
0Related Chains
Source-Backed Evidence Depth
OnKure Therapeutics, Inc. (OKUR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
1Distinct source URLs
8High confidence
0.778Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
OnKure Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
2026-PIPE-INVESTORS
2026-PIPE-INVESTORS
92%
On March 27, 2026, the Company entered into a securities purchase agreement (the “2026 PIPE Purchase Agreement”) with certain institutional accredited investors (the “2026 PIPE Investors”), pursuant …
LEGACY-ONKURE
LEGACY-ONKURE
90%
In connection with the Merger Agreement, certain parties entered into a subscription agreement with the Company to purchase shares of Reneo’s common stock for an aggregate purchase price of $ 65.0 million
MERGER-SUB-I-INC
MERGER-SUB-I-INC
90%
In connection with the Merger Agreement, certain parties entered into a subscription agreement with the Company to purchase shares of Reneo’s common stock for an aggregate purchase price of $ 65.0 million
RADIATE-MERGER-SUB-II-LLC
RADIATE-MERGER-SUB-II-LLC
90%
In connection with the Merger Agreement, certain parties entered into a subscription agreement with the Company to purchase shares of Reneo’s common stock for an aggregate purchase price of $ 65.0 million
OnKure Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
STA-PHARMACEUTICAL-HONG-KONG-LIMITED
STA-PHARMACEUTICAL-HONG-KONG-LIMITED
85%
uction of our product candidates for preclinical studies and clinical trials under the guidance of members of our organization. Furthermore, we rely on single-source suppliers for our drug substance …
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
neral and administrative expenses were $3.9 million for the three months ended March 31, 2026 compared to $4.0 million for the three months ended March 31, 2025. The decrease of approximately $0.1 mi…
EXHIBITS-EXHIBIT-INDEX-INCORPORATED
EXHIBITS-EXHIBIT-INDEX-INCORPORATED
62%
under state tax laws. In addition, California has recently enacted a temporary suspension on the use of state net operating loss carryforwards for certain businesses, which may adversely affect us if…
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
62%
I”) a wholly owned subsidiary of Reneo completed its merger with and into OnKure, Inc. (referred to herein as “Legacy OnKure”), with Legacy OnKure continuing as the surviving entity as a wholly owned…
RADIATE-MERGER-SUB-II-LLC
RADIATE-MERGER-SUB-II-LLC
62%
under state tax laws. In addition, California has recently enacted a temporary suspension on the use of state net operating loss carryforwards for certain businesses, which may adversely affect us if…
RENEO-PHARMACEUTICALS-INC-RADIATE-MERGER-SUB-I-I
RENEO-PHARMACEUTICALS-INC-RADIATE-MERGER-SUB-I-I
62%
under state tax laws. In addition, California has recently enacted a temporary suspension on the use of state net operating loss carryforwards for certain businesses, which may adversely affect us if…
RENEO-RADIATE-MERGER-SUB-I-INC
RENEO-RADIATE-MERGER-SUB-I-INC
62%
I”) a wholly owned subsidiary of Reneo completed its merger with and into OnKure, Inc. (referred to herein as “Legacy OnKure”), with Legacy OnKure continuing as the surviving entity as a wholly owned…
OnKure Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
OKUR-DEBT
Debt stack $409,000
90%
Market cache reports total debt of $409,000.
OKUR-DEBT-11502
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
OnKure Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for OnKure Therapeutics, Inc..
OnKure Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
OKUR-OWNER-RA-CAPITAL-MANAGEMENT-L-P
RA CAPITAL MANAGEMENT, L.P.
90%
13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 51 tracked holders.
OnKure Therapeutics, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
